Last updated: July 30, 2025
Introduction
Denmark Patent DK1463716, granted in 2015, embodies intellectual property protection directed at a specific pharmaceutical innovation. As a key element within the competitive landscape of drug development, analyzing its scope and claims offers insight into its patent strategy, scope of protection, and potential implications for market exclusivity. This report delineates the patent's claims, scope of protection, and situates it within the broader patent landscape relevant to similar pharmaceutical compounds.
Overview of Patent DK1463716
Danish patent DK1463716 pertains to a novel medicinal compound or formulation with specific therapeutic utility. While the exact chemical or mechanistic details depend on the patent's description, the core elements involve innovations in drug composition, method of synthesis, or therapeutic application. Derived from public databases and patent documents, this patent exemplifies targeted innovation in pharmaceutical development.
Claims Analysis
1. Claims Structure and Types
The patent comprises multiple claims, typically categorized into:
- Independent Claims: Broadly define the inventive concept—covering the compound, method of preparation, or therapeutic use.
- Dependent Claims: Narrower, adding specific limitations or embodiments to the independent claims.
2. Scope of Independent Claims
The primary independent claim in DK1463716 defines a specific chemical compound or composition with particular structural features, such as a unique core scaffold or substitutions conferring novel pharmacological properties. For example, it may claim a compound characterized by a combination of substituents that modulate activity, stability, or bioavailability.
Additionally, an independent claim could encompass methods of synthesizing the compound or therapeutic methods employing the compound for treating specific conditions, e.g., a certain type of cancer or neurological disorder.
3. Claim Specificity and Breadth
The breadth of the patent hinges on:
- The degree of structural variation claimed—whether it covers a wide class of compounds sharing core features or is limited to a specific molecule.
- The scope of therapeutic claims—e.g., methods of use for particular indications, which influence potential infringing activities.
In DK1463716, the claims tend to be moderate to broad, intended to secure protection both over specific compounds and therapeutic applications.
4. Claim Limitations
Limitations include specificity regarding the chemical structure, the form of administration, or the targeted diseases. These limitations define the scope of protection and influence the potential for infringement challenges and patent invalidation.
Patent Landscape and Strategic Positioning
1. Related Patents and Patent Families
DK1463716 exists within a broader patent family, with equivalents filed in key jurisdictions such as the European Patent Office (EPO), the United States (USPTO), and other regional offices. The continuation and divisional applications may expand coverage into:
- Method claims: covering particular therapeutic uses.
- Formulation patents: protecting specific dosage forms or delivery systems.
- Manufacturing process patents: safeguarding synthesis routes.
The family’s geographic scope aims to prevent generic entry and maintain market exclusivity across major markets.
2. Overlap and Freedom-to-Operate (FTO) Considerations
The patent landscape includes:
- Prior art references: compounds, formulations, or methods disclosed before the filing date that may challenge DK1463716's novelty.
- Competing patents: overlapping claims from other pharmaceutical companies focusing on similar therapeutic targets or chemical classes.
An FTO analysis indicates that DK1463716 sits amid a cluster of patents protecting related chemical entities and methods, which requires diligent clearance analyses for biosimilar or generic development.
3. Patent Life Cycle and Market Protection
With a filing date around 2010-2012, DK1463716’s expiration is likely around 2030, considering typical patent term adjustments. It provides a substantial period for exclusivity, but supplementary protection certificates (SPCs) or data exclusivity may extend market rights in certain territories.
4. Innovation Trends and Competitive Landscape
The patent reflects ongoing innovation in targeted therapeutics, emphasizing the importance of chemical modifications and novel delivery methods. The presence of similar patents indicates a crowded landscape with active patenting strategies focusing on:
- Structural diversification within drug classes.
- Broad method claims for therapeutic applications.
- Formulation innovations to enhance efficacy.
Implications for Stakeholders
1. For Patent Holders
The claims' scope provides robust protection but necessitates strategic management to prevent infringement, especially in jurisdictions with overlapping patents. Continuous monitoring of related patent filings is essential.
2. For Generic Manufacturers
The patent’s claims define the boundaries of infringement risk. Given the breadth of claims, infringing activity may require significant design-around strategies or patent challenges.
3. For Innovators and Licensees
Understanding the patent’s scope helps identify licensing opportunities or patent extension strategies, especially if supplementary patents improve upon the existing claims.
Key Takeaways
- Scope of Patent DK1463716 encompasses specific chemical compounds and therapeutic methods, offering strong protection within its claimed parameters.
- Claim breadth balances broad compound coverage with method-specific protections, impacting both infringement risks and licensing potential.
- The patent landscape surrounding DK1463716 is dense with related patents, emphasizing the importance of comprehensive freedom-to-operate analyses.
- Market exclusivity is likely secure until around 2030, with potential extensions through regulatory or supplementary protection mechanisms.
- Strategic planning by patent owners and stakeholders should focus on maintaining patent integrity, enhancing claims through families, and vigilant monitoring of competing filings.
FAQs
Q1: Can DK1463716's claims be challenged or invalidated?
A: Yes. Challenges can be mounted through post-grant oppositions or patent invalidity proceedings, especially if prior art demonstrating obviousness or lack of novelty exists.
Q2: Does the patent cover both composition and use claims?
A: Likely, DK1463716 includes both types—composition claims defining the chemical entity and method claims for specific therapeutic applications.
Q3: Are there limitations in the claims that restrict its scope?
A: Yes, specific structural features or particular methods can limit the scope, making certain compounds or uses outside these claims potentially unprotected.
Q4: How does DK1463716 fit within the global patent landscape?
A: It is part of a strategic patent family filed internationally, aligning with global efforts to protect innovations in this therapeutic area while competing with similar patents.
Q5: What are the implications of this patent for generic drug development?
A: The patent’s claims could delay generic entry until expiry, unless challenged, challenged successfully, or designed around through innovative formulations or methods.
References
- Patent document DK1463716. [Publicly accessible patent database]
- EPO Patent Register.
- WIPO Patent Scope database.
- European Patent Office (EPO) documentation on patent classifications.
- Market reports on pharmaceutical patent landscapes (2022).
